Cellectis to Participate in Two Upcoming Investor Conferences in March

New York, NY – March 11, 2022 – Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that management will participate in the Oppenheimer & Co. Annual Healthcare Conference, taking place March 15-17, 2022 as well as the Barclays Global Healthcare Conference, taking place March 15-17. Details for both presentations are below:

Oppenheimer & Co. Annual Healthcare Conference:

Date: March 16

Time: 4:00pm EST

Webcast: https://wsw.com/webcast/oppenheimer20/register.aspx?conf=oppenheimer20&page=clls&url=https://wsw.com/webcast/oppenheimer20/clls/2771748

Barclays Global Healthcare Conference:

Date: March 17

Time: 9:30am EST

Webcast: https://barclays.webcasts.com/starthere.jsp?ei=1536661&tp_key=0d6c4a2a9d&tp_special=8

Live webcasts of these events and a replay of these webcasts will be available under the “Events and Webcasts” section on the Investor page of the of the Company’s at website: https://cellectis.com/en/investors/events-and-webcasts/